Advertisement
Singapore markets close in 2 hours 15 minutes
  • Straits Times Index

    3,326.03
    +18.59 (+0.56%)
     
  • Nikkei

    38,720.47
    -156.24 (-0.40%)
     
  • Hang Seng

    18,030.92
    +93.08 (+0.52%)
     
  • FTSE 100

    8,215.48
    +67.67 (+0.83%)
     
  • Bitcoin USD

    67,397.97
    +62.91 (+0.09%)
     
  • CMC Crypto 200

    1,421.35
    +8.40 (+0.59%)
     
  • S&P 500

    5,421.03
    +45.71 (+0.85%)
     
  • Dow

    38,712.21
    -35.21 (-0.09%)
     
  • Nasdaq

    17,608.44
    +264.89 (+1.53%)
     
  • Gold

    2,328.90
    -25.90 (-1.10%)
     
  • Crude Oil

    78.17
    -0.33 (-0.42%)
     
  • 10-Yr Bond

    4.2950
    -0.1090 (-2.48%)
     
  • FTSE Bursa Malaysia

    1,613.89
    +4.94 (+0.31%)
     
  • Jakarta Composite Index

    6,870.04
    +19.94 (+0.29%)
     
  • PSE Index

    6,423.13
    +13.06 (+0.20%)
     

India's GlaxoSmithKline Pharma's pre-tax profit falls on govt pricing caps

BENGALURU (Reuters) - India's GlaxoSmithKline Pharmaceuticals Ltd reported an 8.6% fall in its pre-tax profit for the fourth quarter on Wednesday, hurt by the government's curbs on pricing of some essential medicines.

Consolidated profit before tax dropped to 1.90 billion rupees ($23.23 million) for the quarter ended March 31, from 2.08 billion rupees a year earlier, the Indian unit of UK's GSK Plc said in an exchange filing.

Revenue from operations at the maker of Augmentin antibiotic and T-Bact ointment fell 2.7% to 7.87 billion rupees.

"A robust underlying volume growth was offset by the impact of National List of Essential Medicines (NLEM) 2022," the company said.

ADVERTISEMENT

GlaxoSmithKline's Ceftum and T-Bact, used to treat bacterial infections, were included in the NLEM list, which mandates those medicines to be sold below a price ceiling set by a government pricing body.

In March, the company said the revenue share of drugs impacted by the pricing cap was at 42% so far in 2023, up from 33% in 2022.

The company plans to mitigate the impact of the price caps by boosting sales volumes of its Ceftum, T-Bact and Augmentin.

Separately, the company recommended a dividend of 32 rupees per share.

Shares of the drugmaker closed 0.43% higher before the results, compared with a 0.45% fall in the benchmark Nifty Pharma index.

($1 = 81.7800 Indian rupees)

(Reporting by Kashish Tandon, Chris Thomas and Manvi Pant in Bengaluru; Editing by Shilpi Majumdar)